Breaking News Bar

Business News and Information

JPMorgan downgrades Moderna on valuation concerns after 380% rally this year

Moderna skyrocketed 384% this year as investors bet it will become one of the first drugmakers to develop a viable coronavirus vaccine.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear